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Take home message: Therapeutic drug monitoring allows for sub-300 mg linezolid dosages once 
daily to successfully achieve PK/PD targets. Let’s confirm these retrospective data in a prospective 
study using dried blood spots. 
 
  
Despite all our efforts, the disease burden of tuberculosis (TB) is not falling fast enough to reach the 
2030 milestone of the End TB strategy [1]. Multidrug-resistant tuberculosis (MDR-TB) remains a 
public health crisis, with low treatment success rates [1]. The repurposed drug linezolid has  emerged 
as a core drug in MDR-TB treatment regimens [2,3], despite its toxicity, e.g. anemia, peripheral 
neuropathy and gastrointestinal disorders, optic neuritis, and thrombocytopenia [4,5].  Currently, 
linezolid is used off-label, as part of Group A “Medicines to be prioritised” of the World Health 
Organization MDR-TB treatment guideline [2] and in several large trials [6], such as the NIX- TB and 
END-TB trials. 
We use a holistic approach to treat MDR-TB, focusing multidisciplinarily on optimizing treatment 
using pharmacokinetics (PK) and pharmacodynamics, assessing and optimizing nutritional status, 
providing physical therapy and social care [7]. Treatment regimens are based on the WHO guidelines, 
but are individualized based on drug susceptibility testing (DST) combined with TDM if the regimen 
consists of second-line drugs or if patients are at risk for PK variability [8]. DST is performed at Dutch 
National Mycobacterial Reference Laboratory (RIVM, Bilthoven, The Netherlands).  
Most patients start on a dose of 600 mg linezolid once daily. After two weeks, a full pharmacokinetic 
curve is obtained for all patients that receive linezolid, after which the dosage is lowered to 300 mg 
once daily. At steady state, the lowered dosage is again checked with TDM. Based on limited 
available literature, we strive for an area under the time – total fraction concentration curve (AUC0-
24h) / minimum inhibitory concentration (MIC) ratio >100 [9]. If TDM allows, the dose of linezolid is 
reduced further to an optimal, lowest dose, with the aim to reduce toxicity of linezolid [4,5,10]. If the 
totalAUC0-24h/MIC ratio of linezolid is high enough, a dose reduction to 200 or even 150 mg of linezolid 
once daily is considered. In this study, we describe the first experiences of the treatment of MDR-TB 
using sub-300 mg dosages. 
We retrospectively searched for inpatients for whom linezolid PK data was collected between 2015-
2018. As routine treatment data were collected retrospectively and anonymously, the Institutional 
Ethical Review Board waived the requirement to obtain informed consent (METc 2013/492). Patients 
that received a sub-300 mg dose of linezolid were included. Baseline characteristics co-morbidities 
(HIV/HBV/HCV/diabetes), MIC for linezolid, treatment regimen, and treatment outcome, were 
obtained from the electronic hospital record and the discharge letter from the treating lung 
physician.  
Twenty-seven patients with linezolid pharmacokinetic data were identified. Of these patients, 18 
(66%) had a final dose ≥300 mg linezolid once daily. Nine (34%) patients received a sub-300 mg dose 
of linezolid and were included in our study (see Table 1). These patients had a median (range) weight 
of 55 (43-77) kg. At admission, patients had a median (range) leucocyte count 6.6 (4.6-10.8) *109/L, 
thrombocytes 324 (238-461) *109/L, and hemoglobin 13.2 (11.8-16.3) g/dL. At admission, one of the 
patients was 32 weeks pregnant. Based on local policy, the individual patient and her preferences, it 
was decided – in contrast with standard practice – that the start of treatment of MDR-TB could be 
postponed until the patient gave birth to a healthy child. 
Four patients had pulmonary TB, two had extra-pulmonary TB, one had miliary TB, one had pleural 
TB, and one had a combination of pulmonary and extra-pulmonary TB. DST revealed that eight 
patients had MDR-TB and one had rifampin resistant TB. The MIC for linezolid of the Mycobacterium 
tuberculosis isolate was 0.25 mg/L for seven patients and 0.5 mg/L for two patients. Based on the 
available totalAUC0-24h/MIC ratios, dosages were lowered to 200 mg once daily in four (15%) patients 
and 150 mg in five (19%) patients.  
The sub-300 mg dosages of linezolid are prepared as capsules at the compounding department of our 
pharmacy. Commercially available linezolid tablets are pulverized and sieved. Lactose-1-water is used 
to create the correct volume of the homogenized powder mixture, after which transparent empty 
capsules are filled. All capsules are checked visually and ten capsules are checked for the correct 
weight and percentage of deviation (≤3%) from the correct weight. The capsules are kept at room 
temperature for a maximum of one year.  
With the sub-300 mg dosages of linezolid, the patients had a median (range) totalAUC0-24h of 50 (49-57) 
mg*h/L. In three cases, there was no AUC0-24h available for the lowest dose due to logistical issues. In 
these cases, the totalAUC0-24h of the lowest dose was calculated using our linezolid pharmacokinetic 
model [11] in MWPharm++ (Mediware, Groningen, the Netherlands). The median (range) 
totalAUC/MIC ratio was 196 (98-276), with all except one patient attaining the target of 100 that is 
used in our clinic, based on a systematic review of literature [12]. Since the AUC/MIC ratio of that 
patient was 98, we did not increase the dose.  
As soon as the patients  received and tolerated their tailor-made regimen, treatment was continued 
at home. The included patients finished their treatment as outpatients under supervision of the staff 
of our center. At discharge, patients had a median (range) leucocyte count 4.7 (3.7-7.3) *109/L, 
thrombocytes 270 (159-327) *109/L, and hemoglobin 13.7 (11.1-16.4) g/dL. None of the patients had 
significant adverse events or toxicity from the linezolid dosages they received. Despite the fact that 
we cannot draw any conclusions about the safety or efficacy of our approach, after discharge, all 
except one patient (lost to follow-up) finished their treatment regimens successfully. 
This study describes the treatment of TB with linezolid dosages lower than 300 mg. Linezolid is 
known for its side effects, with a meta-analysis showing adverse events in 58.9% of patients with 
linezolid containing regimens to treat MDR-TB [4]. Higher dosages of linezolid (i.e. >600mg) show 
more side effects than lower dosages (i.e. between 300-600mg) [4,5]. In our study, in nine out of 27 
patients, TDM combined with DST allowed for lowering the linezolid dosage to 200 mg or 150 mg 
once daily, thereby possibly limiting the number of side effects even further.  
Obviously, there are limitations to this study, such as the small number of patients, missing data, and 
the retrospective character of the study. We do not yet have long term follow-up data, although so 
far no relapses occurred. We only performed PK analysis of blood samples, not of the affected tissue 
[13,14]. Also, the applicability of this study to low-income countries, where MDR-TB is most 
prevalent, might be limited. For instance, a compounding unit in a pharmacy that is able to produce 
linezolid capsules might not be readily available. In these cases, one could perhaps consider using 
quarter tablets of 600 mg linezolid (or 300 mg every two days) to administer 150 mg once daily, 
however one must then make sure splitting is done in a correct and safe manner. We have not 
studied the bioequivalence of our capsules. However, since the absorption of linezolid is usually fast 
and complete, PK of linezolid is non-linear, and we performed TDM, we do not expect this to impact 
the treatment outcome. Furthermore, TDM is not available everywhere, but dried blood spots (DBS) 
[15] combined with limited sampling methods [11] might allow for this strategy to be implemented in 
other settings. There is still an ongoing discussion on the most appropriate PK/PD target for linezolid. 
In our clinic, we use an AUC/MIC target of > 100 using the total fraction concentration of linezolid, 
based on a recent manuscript as a part of a WHO initiative to systematically review the current 
recommended dose for second-line TB drugs [12]. In future research, besides applicability and 
implementation of TDM in low-income countries, cost-benefit should also be studied. By 
administering lower dosages of linezolid in patients if the AUC0-24h and MIC allows, drug costs per 
patient of this rather expensive drug is reduced. Finally, lower dosing might reduce dose-related 
toxicity allowing treatment for a prolonged period of time [16].  
In conclusion, sub-300 mg doses of linezolid can achieve putative PK/PD targets in certain patients. A 
large prospective study with DBS might provide us with valuable information on the possibilities to 
implement this strategy in other settings. 
  
Table 1 baseline characteristics and pharmacokinetic/pharmacodynamic results patients receiving 
sub-300mg dosages of linezolid as a part of their tuberculosis treatment regimens 
Parameter Value 
Subjects 9 
Age (years) 27 (17-55) 
Male 4 (44%) 
Weight (kg) 55 (43-77) 
Height (m) 1.65 (1.55-1.88) 
Body mass index (kg/m2) 20.5 (16.2-24.1) 
Continent of origin  
 Asia 4 (44%) 
 Europe 4 (44%) 
 Africa 1 (12%) 
HIV, Hepatitis B or C positive 0/7 
  
Drug susceptibility  
 Multidrug-resistant 8 
 Rifampicin-resistant 1 
Treatment regimen  
 Linezolid 9/9 
 Moxifloxacin 9/9 
 Amikacin 8/9 
 Ethambutol 8/9 
 Clofazimine 6/9 
 Pyrazinamide 5/9 
 Protionamide 2/9 
 (High dose) isoniazid 2/9 
 Cycloserin 1/9 
  
Linezolid  
Lowest dose (once daily)  
 200 mg  4 (44%) 
 150 mg 5 (56%) 






 0.25 mg/L 7 (78%) 
 0.5 mg/L 2 (22%) 
totalAUC0-24h/MIC 196 (98-276) 
All data are presented as median (range) or number (percentage); linezolid cocentrations are presented as total fraction concentrations 
(e.g. totalAUC); HIV: human immunodeficiency virus; weight, height, and body mass index were collected at admission; MIC: minimum 
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